Member Info for ShearClass

Yep, looking strong after that spike was digested...agree on a steady move up for the rest of the day!

The scramble is already on - this is a nightmare to buy when it’s on the rise!

Wow, ask rising like a rocket - Has Norris stopped at 2m / 9% ??

Bid chasers at 32.5p, makes me laugh every time when the bid rises and people sell straight away. Some big delayed buys will show IMO

Steven, if you held 16% of a business and it rose by 400% I can completely understand why you would sell some of it... It’s happened with almost of the Covid companies as the increased liquidity provides an opportunity to sell in large quantity that wouldn’t normally exist. ODX had a forced seller at 21p, once clear it’s not looked back.

Seriously who cares about Doc Holliday? He clearly has zero scientific knowledge and is looking for reasons to criticise BRH. There is no impartiality or interest about what Aptamer Group / Paraytec can offer so he is clearly negatively biased rather than balanced.

There has been some great research this weekend & as I expect we’ll have news this week on progress. If you don’t think BRH is worth it at £11m market cap then go elsewhere, that is everyone’s choice!

Agree Torreaguas, fact is we saw a similar move after the first placing. Rose from 19p to 40p and then back down to 25p, and that was before the second placing at 22p was announced.

This time we have done 22p to 50p and then back down. In my opinion I t’ll be some placing shares being sold (and there were only 3m issued) and PI’s who bought with no research at 45p + and lost their nerve when it fell back.

What excites me is that Paraytec have all the hallmarks of a hidden gem. Take the current project below as an example, where they are involved in a consortium that includes GSK.

“The first key R&D project is in Paraytec's traditional market of research instrumentation for the biopharmaceutical sector. Paraytec is a key member of a consortium including Malvern Panalytical, GSK, Medimmune, Fujifilm Diosynth Biotechnologies and others who have developed prototype instruments which will shortly be evaluated by the drug development partners. These instruments are aimed at protein-based pharmaceuticals, to detect instabilities that can cause drug molecules to aggregate resulting in a reduction of their therapeutic effectiveness and possible unwanted side-effects for the patient.”

The likelihood of a collaboration between Aptamer Group, Paraytec & Cytiva has increased significantly since close on Thursday, so I think we’ll see a step up in buying next week which will propel the share price to the next level of 50p + .

IMO to get beyond the 50-60p range we’ll need an RNS conforming everything. If we get this then £1 and beyond comes into view.

Should be a very exciting week!

With a £235m market cap at AVCT versus just £11m here, the upside appears significantly higher with BRH & Paraytec. There is also no reason at all that both companies can’t be commercially successful, so it doesn’t need to be an us against them situation...

Some bank holiday reading for you all;

Could Paraytec manufacture a biosensor as described in the journal below?!

Thursday’s RNS:

“Using Paraytec's imaging capability in partnership with aptamers from Aptamer Group which bind to the spike protein on the virus, the objective is to develop a portable test, which can generate a result in a matter of minutes from a swab provided at the test location and require no specialist skills to be operated.”

2019 Journal:

Aptamer based nanobiosensors: Promising healthcare devices

https://www.sciencedirect.com/science/article/pii/S1319016418303852

“4. Conclusion
In the past decade, there has been a dramatic increase in research for aptamers due to their various advantages in biosensor field.

Nonmaterials used in the development of aptamer-based biosensors have greatly helped in the discovery of important and versatile diagnostic devices.

Owing to their small size, portability, easy to use, cost efficiency, non toxicity and disposability. These aptamer based biosensors more interesting for application in clinical analysis.

In this review article, the types of aptasensors, their applications in the field of mainly in the field of medical diagnosis a nanomedicine and biotechnology have been reviewed.

Aptamers are manufactured in large number and modification by the use of different materials makes them versatile compounds to be used in variety of clinical applications. With the continued progress in the field of aptasensors instrumentation of biosensors is becoming cost effective, easy to operate and fast.

But there are still many challenges as discussed in the review which remain to be addressed leading to widespread applicability along with better precision”.

An interesting post from Cytiva yesterday that provides more insight on the influence of Klaus Hochleitner in the recent collaborations with Avacta, Genedrive & others.

If Cytiva agreed to collaborate with Aptamer Group, the key question would be what involvement would Paraytec have?

We just need the project confirmation RNS to rubber stamp the agreement and things will really start to move. Very exciting!

https://medium.com/discovery-matters/biotech-tackles-coronavirus-the-scientific-frontier-a50e0d1b740b

“Back in February, Klaus Hochleitner, Global Product Specialist Diagnostics at Cytiva and an industry veteran with over 30 years of diagnostics expertise, offered support to those working on tests via a LinkedIn post. This led to a collaboration with the Canada-based diagnostics company Sona Nanotech to complete the development of Sona’s rapid response lateral flow test.”

Klaus Hochleitner says: “This ties into our daily mission of advancing and accelerating therapeutics, by supporting the global scientific community working tirelessly to address the COVID-19 outbreak.”

“Another collaboration that arose from Klaus’ LinkedIn post was with UK-based life sciences company, Avacta. They are developing an Affimer-based rapid test that could detect the coronavirus infection in minutes, with no need for laboratory equipment.”

“We also recently teamed with Genedrive, a molecular diagnostics company, to support the development of a coronavirus test based on the polymerase chain reaction (PCR) — a highly efficient and commonly used laboratory method. The test will combine Genedrive’s PCR chemistry with our LyoStable stabilization technology, which would allow the manufacturing of more than 10,000 tests per hour. Producing such large volumes of tests could have a significant impact on controlling the pandemic.”

“There is so much hope that these collaborations will lead to the scientific breakthroughs needed to overcome COVID-19. The unprecedented mobilization of the scientific community is creating a new culture of cross-disciplinary cooperation, openness, and data sharing. At Cytiva, we have a strong heritage of collaboration and scientific discovery.”

“Stay tuned as we continue to bring you more stories on how we combat the COVID-19 pandemic.”

The Global Lead Technology Product Specialist at Cytiva, Klaus Hochleitner, liked the LinkedIn post that was shared earlier. Huge.

@Looed, if anything this is a positive for BRH / Aptamer group as it shows that it’s possible. As with PCR testing no single company will take over the world, they can’t worry about competitors, only refining / proving their solution works.

Agreed! And it can’t be far away now...

From yesterday’s RNS

“Using Paraytec's imaging capability in partnership with aptamers from Aptamer Group which bind to the spike protein on the virus, the objective is to develop a portable test”

And tonight’s Aptamer Group update

“We are aiming to have specific binders developed and ready for testing in multiple formats over the next few weeks”.

Once they have successfully created the Aptamers surely that’s where Paraytec get involved? As testing would involve using their imaging capabilities to check test specificity etc...

Fingers crossed we get an RNS on Monday Morning with project sign off.

Just posted this evening; Part II - Specific Aptamers Developed to COVID19 Spike protein in 10 days https://www.linkedin.com/pulse/part-ii-specific-aptamers-developed-covid19-spike-protein-tolley “Last week I reported our preliminary data demonstrating that we have developed high affinity aptamer populations against SARS-CoV-2 spike protein S1. Once again I’m excited and incredibly proud to announce the results from the next evolution of the aptamer selection process. This week, our lab team have worked around the clock focusing on refining the aptamer population by removing those aptamers that bind to spike proteins from other coronaviruses. This is important in the development of an accurate test, capable of determining if people are infected with the COVID-19 virus.This evening, our kinetics team tested the refined aptamer population to see if we’ve made our aptamers more specific for the COVID-19 spike protein. The results show that while the population does still bind to the spike protein from the related coronavirus ‘MERS’; it binds significantly better to the SARS-CoV-2 protein.This is fantastic news as we are now confident that we have multiple specific binders able to bind to SARS-CoV-2 but not other coronaviruses. This is something that many other tests have failed to do – potentially leading to incorrect diagnosis. Figure 1. Biolayer Interferometry assay demonstrates the interaction between aptamer population (‘pool 7S’) and the S1 spike protein from either SARS-CoV-2 (blue) or MERS (red). The pool shows significantly higher binding to the COVID-19 spike protein.Next week we plan to refine the population even further, by removing aptamers which bind to other coronaviruses. We are aiming to have specific binders developed and ready for testing in multiple formats over the next few weeks.In the next stage of the process, we will be test the aptamers we identify to see if they inhibit interaction of the virus protein and the ACE2 receptor; an essential process for viral infection. Our preliminary tests show some promise”.

Completely agree - don't forget that the week after NCYT had it's first rise to 50p it fell back to 30p... very much looking forward to seeing the updates from Aptamer Group, confirmation of the test proceeding & detail around the role played by Paraytec / Braveheart will be spark that sets this on the way to £1 and beyond.

Actually ignore that - they haven't reduced it's just that their shareholding has been diluted by the recent placing...

There is our seller - D C Thomson reduced by 1.14% to 7.59% on 5th May, of course that was before the RNS yesterday morning, so they could well be nearly out given the last two days volume.

Ah, I hadn't seen the more recent reply 5 hours ago stating that they were in discussions with several companies...!

Add in the fact that Paraytec are definitively involved as per the Aptamer Group partnerships page + yesterday's RNS & I can't believe this is still only a £10m market cap.